Motif's iclaprim meets in second Phase III for ABSSSIs

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) reported top-line data showing that iclaprim (MTF-100) met the primary endpoint of non-inferiority to vancomycin in the Phase III REVIVE-2 trial to treat acute bacterial skin and skin structure infections (ABSSSIs). The company plans to submit an

Read the full 426 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE